BCYC
Price
$8.19
Change
+$0.41 (+5.27%)
Updated
May 8, 04:59 PM (EDT)
Capitalization
538.8M
84 days until earnings call
STRO
Price
$0.95
Change
-$0.04 (-4.04%)
Updated
May 8, 04:59 PM (EDT)
Capitalization
80.28M
11 days until earnings call
Ad is loading...

BCYC vs STRO

Header iconBCYC vs STRO Comparison
Open Charts BCYC vs STROBanner chart's image
Bicycle Therapeutics
Price$8.19
Change+$0.41 (+5.27%)
Volume$5.64K
Capitalization538.8M
Sutro Biopharma
Price$0.95
Change-$0.04 (-4.04%)
Volume$7.23K
Capitalization80.28M
BCYC vs STRO Comparison Chart
Loading...
BCYC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
STRO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BCYC vs. STRO commentary
May 09, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BCYC is a Hold and STRO is a Hold.

Ad is loading...
COMPARISON
Comparison
May 09, 2025
Stock price -- (BCYC: $7.78 vs. STRO: $0.99)
Brand notoriety: BCYC and STRO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BCYC: 170% vs. STRO: 107%
Market capitalization -- BCYC: $538.8M vs. STRO: $80.28M
BCYC [@Biotechnology] is valued at $538.8M. STRO’s [@Biotechnology] market capitalization is $80.28M. The market cap for tickers in the [@Biotechnology] industry ranges from $301.75B to $0. The average market capitalization across the [@Biotechnology] industry is $2.22B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BCYC’s FA Score shows that 1 FA rating(s) are green whileSTRO’s FA Score has 1 green FA rating(s).

  • BCYC’s FA Score: 1 green, 4 red.
  • STRO’s FA Score: 1 green, 4 red.
According to our system of comparison, both BCYC and STRO are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BCYC’s TA Score shows that 3 TA indicator(s) are bullish while STRO’s TA Score has 5 bullish TA indicator(s).

  • BCYC’s TA Score: 3 bullish, 6 bearish.
  • STRO’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, STRO is a better buy in the short-term than BCYC.

Price Growth

BCYC (@Biotechnology) experienced а -9.11% price change this week, while STRO (@Biotechnology) price change was -5.39% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.88%. For the same industry, the average monthly price growth was +15.29%, and the average quarterly price growth was -13.75%.

Reported Earning Dates

BCYC is expected to report earnings on Jul 31, 2025.

STRO is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Biotechnology (-3.88% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BCYC($539M) has a higher market cap than STRO($80.3M). BCYC (-44.429) and STRO (-46.011) have similar YTD gains . BCYC has higher annual earnings (EBITDA): -164.89M vs. STRO (-186.81M). BCYC has more cash in the bank: 880M vs. STRO (317M). BCYC has less debt than STRO: BCYC (9.49M) vs STRO (23.2M). STRO has higher revenues than BCYC: STRO (62M) vs BCYC (35.3M).
BCYCSTROBCYC / STRO
Capitalization539M80.3M671%
EBITDA-164.89M-186.81M88%
Gain YTD-44.429-46.01197%
P/E RatioN/AN/A-
Revenue35.3M62M57%
Total Cash880M317M278%
Total Debt9.49M23.2M41%
FUNDAMENTALS RATINGS
BCYC vs STRO: Fundamental Ratings
BCYC
STRO
OUTLOOK RATING
1..100
1616
VALUATION
overvalued / fair valued / undervalued
1..100
24
Undervalued
32
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
8697
PRICE GROWTH RATING
1..100
6558
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BCYC's Valuation (24) in the null industry is in the same range as STRO (32) in the Pharmaceuticals Major industry. This means that BCYC’s stock grew similarly to STRO’s over the last 12 months.

BCYC's Profit vs Risk Rating (100) in the null industry is in the same range as STRO (100) in the Pharmaceuticals Major industry. This means that BCYC’s stock grew similarly to STRO’s over the last 12 months.

BCYC's SMR Rating (86) in the null industry is in the same range as STRO (97) in the Pharmaceuticals Major industry. This means that BCYC’s stock grew similarly to STRO’s over the last 12 months.

STRO's Price Growth Rating (58) in the Pharmaceuticals Major industry is in the same range as BCYC (65) in the null industry. This means that STRO’s stock grew similarly to BCYC’s over the last 12 months.

STRO's P/E Growth Rating (100) in the Pharmaceuticals Major industry is in the same range as BCYC (100) in the null industry. This means that STRO’s stock grew similarly to BCYC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BCYCSTRO
RSI
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
85%
Momentum
ODDS (%)
Bearish Trend 2 days ago
83%
Bullish Trend 2 days ago
86%
MACD
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 3 days ago
80%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
88%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
81%
Advances
ODDS (%)
Bullish Trend 7 days ago
82%
Bullish Trend 7 days ago
80%
Declines
ODDS (%)
Bearish Trend 3 days ago
87%
Bearish Trend 3 days ago
88%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
88%
Aroon
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
89%
View a ticker or compare two or three
Ad is loading...
BCYC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
STRO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GTTMX18.080.12
+0.67%
Glenmede Total Market Plus Eq Ptf
CABDX6.09N/A
N/A
AB Relative Value A
NPNRX45.07N/A
N/A
Neuberger Berman Large Cap Value R3
EISAX25.67N/A
N/A
Carillon ClariVest Intl Stock A
WIGOX4.15N/A
N/A
Wasatch Global Opportunities Instl

BCYC and

Correlation & Price change

A.I.dvisor indicates that over the last year, BCYC has been loosely correlated with INO. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if BCYC jumps, then INO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BCYC
1D Price
Change %
BCYC100%
+5.14%
INO - BCYC
54%
Loosely correlated
+2.92%
XNCR - BCYC
53%
Loosely correlated
-5.61%
RPTX - BCYC
51%
Loosely correlated
+2.26%
RLAY - BCYC
48%
Loosely correlated
-6.35%
RCKT - BCYC
46%
Loosely correlated
+6.18%
More

STRO and

Correlation & Price change

A.I.dvisor indicates that over the last year, STRO has been loosely correlated with ALGS. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if STRO jumps, then ALGS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To STRO
1D Price
Change %
STRO100%
+4.56%
ALGS - STRO
44%
Loosely correlated
-4.80%
ATXS - STRO
42%
Loosely correlated
+1.14%
TCRX - STRO
41%
Loosely correlated
N/A
TRDA - STRO
41%
Loosely correlated
-2.04%
ERAS - STRO
40%
Loosely correlated
-2.00%
More